Our Focus on Immuno-Oncology
In the field of immuno-oncology, the STAM™ mouse is the most pathologically suitable model for developing new therapeutic drugs for liver cancer.
The utilization of STAM™ mouse enables non-clinical research for the development of liver cancer therapeutics targeting immune cells, tumor microenvironment, and genetic mutations.
NEWS RELEASE
A New Phase in MASH Therapeutics: Resmetirom (THR-β Agonist) and Semaglutide (GLP-1 Receptor Agonist)
In 2024, the U.S. FDA approved Resmetirom (a THR-β agonist) as the first therapeutic agent for MASH. In August…
New
Stem Cell Res Ther.
MicroRNA-4516 in extracellular vesicles-derived mesenchymal stem cells suppressed integrin αV-mediated lung fibrosis ( doi: 10.1186/s13287-025-04559-0.)
APAP-induced acute liver failure model
The APAP-induced acute liver failure model (Acetaminophen) makes use of the over dosing effects of this widely used antipyretic and analgesic drug. An overdose of APAP can cause severe liver damage resulting in ALF.
